Ember Therapeutics, Inc. (EMBT)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2014 | 17.42 Thousand USD | 57.27% |
| 2013 | 11.07 Thousand USD | 40.77% |
| 2012 | 7869.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2015 Q2 | 5844.00 USD | 54.2% |
| 2015 Q3 | -252.00 USD | -104.31% |
| 2015 Q1 | 3790.00 USD | -16.67% |
| 2014 Q1 | 2898.00 USD | -28.41% |
| 2014 FY | 17.42 Thousand USD | 57.27% |
| 2014 Q4 | 4548.00 USD | 15.93% |
| 2014 Q3 | 3923.00 USD | -35.18% |
| 2014 Q2 | 6052.00 USD | 108.83% |
| 2013 FY | 11.07 Thousand USD | 40.77% |
| 2013 Q4 | 4048.00 USD | 4.79% |
| 2013 Q1 | 1816.00 USD | 0.0% |
| 2013 Q2 | 1350.00 USD | -25.66% |
| 2013 Q3 | 3863.00 USD | 186.15% |
| 2012 FY | 7869.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 29.55 Million USD | 99.941% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 95.528% |
| Nascent Biotech, Inc. | 2.22 Million USD | 99.219% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 95.807% |
| Qrons Inc. | 643.67 Thousand USD | 97.294% |
| Rebus Holdings, Inc. | 664 Thousand USD | 97.376% |
| Skye Bioscience, Inc. | 13.54 Million USD | 99.871% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 99.953% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.97% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 99.891% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 99.654% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | 98.695% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.98% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 99.646% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 93.344% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.98% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 99.403% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 98.84% |
| Mesoblast Limited | 5.9 Million USD | 99.705% |
| Marizyme, Inc. | 19.23 Million USD | 99.909% |
| Genus plc | 147.7 Million USD | 99.988% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 99.802% |
| Pharming Group N.V. | 225.49 Million USD | 99.992% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 99.15% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 98.701% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 99.791% |
| ContraFect Corporation | 56.88 Million USD | 99.969% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 99.605% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 98.822% |
| IMV Inc. | 37.7 Million USD | 99.954% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 99.376% |
| MultiCell Technologies, Inc. | 567.42 USD | -2970.213% |
| ONE Bio Corp. | 6.44 Million USD | 99.73% |
| Accustem Sciences Inc. | 3.74 Million USD | 99.535% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.98% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | 96.725% |
| Q BioMed Inc. | 3.43 Million USD | 99.493% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 99.93% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 99.337% |
| Biomind Labs Inc. | 994.18 Thousand USD | 98.248% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.982% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 99.01% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 99.741% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 99.066% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 169.684% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 99.051% |
| GB Sciences, Inc. | 1.42 Million USD | 98.774% |
| Alpha Cognition Inc. | 9.7 Million USD | 99.821% |
| HST Global, Inc. | 140.9 Thousand USD | 87.637% |
| CSL Limited | 3.44 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 98.451% |
| Halberd Corporation | 74.84 Thousand USD | 76.723% |
| Enzolytics Inc. | 2.17 Million USD | 99.201% |
| Agentix Corp. | 1.37 Million USD | 98.73% |
| Resverlogix Corp. | 12.71 Million USD | 99.863% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 99.523% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.999% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 98.331% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 99.276% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 98.897% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 99.488% |
| AVAX Technologies, Inc. | 7.31 Million USD | 99.762% |
| Zenith Capital Corp. | 8.94 Million USD | 99.805% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.998% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 99.29% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | 89.843% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 99.093% |
| Kadimastem Ltd | 2.41 Million USD | 99.277% |
| Helix BioMedix, Inc. | 1.97 Million USD | 99.117% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 99.84% |
| BioStem Technologies, Inc. | 22.97 Million USD | 99.924% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | 90.401% |
| LadRx Corporation | 3.81 Million USD | 99.543% |
| Cell Source, Inc. | 4.32 Million USD | 99.597% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 98.114% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 98.114% |
| NovAccess Global Inc. | 2.46 Million USD | 99.294% |
| Affymax, Inc. | 39.38 Million USD | 99.956% |
| Itoco Inc. | 919.14 Thousand USD | 98.105% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 99.589% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 98.443% |
| Mobile Lads Corp. | 554.54 Thousand USD | 96.859% |
| CytoDyn Inc. | 18.05 Million USD | 99.904% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | 30.784% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | 92.084% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 98.773% |
| SYBLEU INC | 160.87 Thousand USD | 89.171% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 99.041% |
| International Stem Cell Corporation | 5.27 Million USD | 99.669% |
| Bioxytran, Inc. | 3.82 Million USD | 99.544% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | 66.907% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | 14.364% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 99.952% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 98.923% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 97.632% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 99.44% |
| Neutra Corp. | 243.82 Thousand USD | 92.855% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 99.9% |
| PureTech Health plc | 144.59 Million USD | 99.988% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 99.915% |
| IXICO plc | 4.7 Million USD | 99.63% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 99.802% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.985% |
| CSL Limited | 3.89 Billion USD | 100.0% |
| Cellectis S.A. | 97.32 Million USD | 99.982% |